AstraZeneca $AZN fell 9%, erasing roughly $27B in market value, after Wainua missed the primary endpoint in a late-stage ATTR-CM heart trial. The miss puts a larger cardiac indication behind the drug under pressure while existing approvals remain intact.
The discussion centered on a practical point: reliable agents depend on data quality, evaluation, recovery, and observability more than workflow diagrams.
Novo Nordisk raised its full-year 2026 guidance after Q1 sales hit $15.2 billion (+32% constant currency), driven by the oral Wegovy pill which now commands 65% of new GLP-1 prescriptions in the United States.
Organon $OGN rose about 31% before the bell after Sun Pharma $SUNPHARMA agreed to pay $14 a share in cash, valuing the target at $11.75B including debt. Sun said the combination would create a $12.4B-revenue pharma group with a larger women’s-health and biosimilars footprint.